GB0213622D0 - Vaccine Corporation - Google Patents

Vaccine Corporation

Info

Publication number
GB0213622D0
GB0213622D0 GBGB0213622.4A GB0213622A GB0213622D0 GB 0213622 D0 GB0213622 D0 GB 0213622D0 GB 0213622 A GB0213622 A GB 0213622A GB 0213622 D0 GB0213622 D0 GB 0213622D0
Authority
GB
United Kingdom
Prior art keywords
vaccine
corporation
vaccine corporation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0213622.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FINLAY INST
GlaxoSmithKline Biologicals SA
Original Assignee
FINLAY INST
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FINLAY INST, GlaxoSmithKline Biologicals SA filed Critical FINLAY INST
Priority to GBGB0213622.4A priority Critical patent/GB0213622D0/en
Publication of GB0213622D0 publication Critical patent/GB0213622D0/en
Priority to MXPA04012568A priority patent/MXPA04012568A/es
Priority to US10/529,064 priority patent/US20060110412A1/en
Priority to BR0311777-4A priority patent/BR0311777A/pt
Priority to CA002488782A priority patent/CA2488782A1/en
Priority to RU2005100509/13A priority patent/RU2005100509A/ru
Priority to KR1020047019991A priority patent/KR20050049431A/ko
Priority to CL200301192A priority patent/CL2003001192A1/es
Priority to PCT/EP2003/006094 priority patent/WO2003105890A2/en
Priority to EP03735599A priority patent/EP1565211A2/en
Priority to NZ560766A priority patent/NZ560766A/en
Priority to CNB038162822A priority patent/CN100387298C/zh
Priority to JP2004512791A priority patent/JP2005531614A/ja
Priority to AU2003236734A priority patent/AU2003236734A1/en
Priority to UY27843A priority patent/UY27843A1/es
Priority to PE2003000583A priority patent/PE20040562A1/es
Priority to ARP030102096A priority patent/AR040204A1/es
Priority to ZA200409547A priority patent/ZA200409547B/en
Priority to CU20040285A priority patent/CU23552A1/es
Priority to NO20050132A priority patent/NO20050132L/no
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB0213622.4A 2002-06-13 2002-06-13 Vaccine Corporation Ceased GB0213622D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB0213622.4A GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation
AU2003236734A AU2003236734A1 (en) 2002-06-13 2003-06-10 Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles
PCT/EP2003/006094 WO2003105890A2 (en) 2002-06-13 2003-06-10 Vaccine composition
NZ560766A NZ560766A (en) 2002-06-13 2003-06-10 Vaccine composition comprising mixtures of multivalent meningococcal outer membrane vesicles
BR0311777-4A BR0311777A (pt) 2002-06-13 2003-06-10 Composição de vesìcula meningocócica multivalente, vacina para o tratamento de doença neisserial, métodos para fabricação de composição de vesìcula meningocócica multivalente e para prevenção ou tratamento de doença neisserial, e, uso de uma quantidade imunologicamente eficaz da vacina
CA002488782A CA2488782A1 (en) 2002-06-13 2003-06-10 Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles
RU2005100509/13A RU2005100509A (ru) 2002-06-13 2003-06-10 Вакцинная композиция
KR1020047019991A KR20050049431A (ko) 2002-06-13 2003-06-10 다가의 메닝고코쿠스 외부 멤브레인 소낭의 혼합물을포함하는 백신
CL200301192A CL2003001192A1 (es) 2002-06-13 2003-06-10 Composicion inmunogenica meningococica multivalente, de vesiculas de membrana externa, que comprende una vesicula con actividad homologa de un subserotipo prevalente en un pais y otra vesicula con actividad heterologa, que tiene disminuida una protei
MXPA04012568A MXPA04012568A (es) 2002-06-13 2003-06-10 Vacuna que comprende mezclas de vesiculas de membrana externa meningococales multivalentes.
EP03735599A EP1565211A2 (en) 2002-06-13 2003-06-10 Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles
US10/529,064 US20060110412A1 (en) 2002-06-13 2003-06-10 Vaccine composition
CNB038162822A CN100387298C (zh) 2002-06-13 2003-06-10 疫苗组合物
JP2004512791A JP2005531614A (ja) 2002-06-13 2003-06-10 ワクチン組成物
ARP030102096A AR040204A1 (es) 2002-06-13 2003-06-11 Composicion de vacuna meningococica multivalente
UY27843A UY27843A1 (es) 2002-06-13 2003-06-11 Composicion de vacuna
PE2003000583A PE20040562A1 (es) 2002-06-13 2003-06-11 Vacunas que comprenden mezclas de cepas meningococicas multivalentes
ZA200409547A ZA200409547B (en) 2002-06-13 2004-11-25 Vaccine comprins mixtures of multivalent menigococcal outer membrane vesciles
CU20040285A CU23552A1 (es) 2002-06-13 2004-12-10 Composición vacunal
NO20050132A NO20050132L (no) 2002-06-13 2005-01-11 Vaksinesammensetning som omfatter blanding av multivalente meningokokk yttermembran vesikler

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0213622.4A GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation

Publications (1)

Publication Number Publication Date
GB0213622D0 true GB0213622D0 (en) 2002-07-24

Family

ID=9938532

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0213622.4A Ceased GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation

Country Status (20)

Country Link
US (1) US20060110412A1 (https=)
EP (1) EP1565211A2 (https=)
JP (1) JP2005531614A (https=)
KR (1) KR20050049431A (https=)
CN (1) CN100387298C (https=)
AR (1) AR040204A1 (https=)
AU (1) AU2003236734A1 (https=)
BR (1) BR0311777A (https=)
CA (1) CA2488782A1 (https=)
CL (1) CL2003001192A1 (https=)
CU (1) CU23552A1 (https=)
GB (1) GB0213622D0 (https=)
MX (1) MXPA04012568A (https=)
NO (1) NO20050132L (https=)
NZ (1) NZ560766A (https=)
PE (1) PE20040562A1 (https=)
RU (1) RU2005100509A (https=)
UY (1) UY27843A1 (https=)
WO (1) WO2003105890A2 (https=)
ZA (1) ZA200409547B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
PL1973564T3 (pl) * 2005-12-22 2017-04-28 Glaxosmithkline Biologicals S.A. Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
US8945582B2 (en) 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
WO2009050586A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS
EP2235531B1 (en) * 2008-02-01 2015-01-14 Sanofi Pasteur Limited Assay for diagnosing streptococcus pneumoniae
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
CN102740882A (zh) 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
JP5860402B2 (ja) * 2009-10-08 2016-02-16 イオン メディックス インコーポレイテッド 室内空気由来細胞外ベシクルを含む組成物及びその用途
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
SG10201501980SA (en) 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
CN102802664B (zh) * 2009-12-22 2017-04-05 赛诺菲巴斯德有限公司 免疫原性组合物
CN102802662A (zh) 2010-03-18 2012-11-28 诺华有限公司 用于脑膜炎球菌血清组b的含佐剂疫苗
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2011127302A2 (en) * 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
BR112013005626B1 (pt) * 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
JP5957541B2 (ja) 2012-02-02 2016-07-27 ノバルティス アーゲー 髄膜炎菌における増加したタンパク質発現のためのプロモータ
JP2015517089A (ja) 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
MX357538B (es) 2012-06-14 2018-07-13 Novartis Ag Vacunas para meningococo de serogrupo x.
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化psa組成物および方法
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
US12161707B2 (en) 2016-09-02 2024-12-10 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
AU2021364838A1 (en) * 2020-10-23 2023-06-08 Omvax, Inc. Compositions and methods for vaccination against neisseria gonorrhoeae
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL338146A1 (en) * 1997-07-17 2000-09-25 North American Vaccine Immunogenic complex combinations consisting of meningococcal porine of b group and h. influenzae polysaccharide
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6936261B2 (en) * 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis

Also Published As

Publication number Publication date
CA2488782A1 (en) 2003-12-24
WO2003105890A2 (en) 2003-12-24
AR040204A1 (es) 2005-03-16
CU23552A1 (es) 2010-07-20
RU2005100509A (ru) 2006-06-10
NO20050132L (no) 2005-02-11
BR0311777A (pt) 2005-03-29
AU2003236734A1 (en) 2003-12-31
PE20040562A1 (es) 2004-10-19
UY27843A1 (es) 2003-12-31
WO2003105890A3 (en) 2004-03-25
MXPA04012568A (es) 2005-09-21
CN1668329A (zh) 2005-09-14
CN100387298C (zh) 2008-05-14
US20060110412A1 (en) 2006-05-25
CL2003001192A1 (es) 2005-01-07
ZA200409547B (en) 2006-07-26
KR20050049431A (ko) 2005-05-25
NO20050132D0 (no) 2005-01-11
JP2005531614A (ja) 2005-10-20
EP1565211A2 (en) 2005-08-24
NZ560766A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
GB0213622D0 (en) Vaccine Corporation
GB0226722D0 (en) Vaccine
GB0202901D0 (en) Novel vaccine
GB0225788D0 (en) Vaccine
GB0329146D0 (en) Vaccine
GB0225786D0 (en) Vaccine
GB0212046D0 (en) Vaccines
GB0228715D0 (en) Vaccine
GB0218921D0 (en) Novel vaccine
GB0209878D0 (en) Vaccine
PL376534A1 (pl) Szczepionka
GB0305794D0 (en) Vaccine
IL173921A0 (en) Vaccine
GB0330079D0 (en) Vaccine
GB0305793D0 (en) Vaccine
AU2003237701A8 (en) Vaccines
IL156434A0 (en) Vaccine
GB0206595D0 (en) Vaccine
GB0223355D0 (en) Vaccine
GB0226179D0 (en) Vaccine
GB0219626D0 (en) Vaccine
GB0206575D0 (en) Vaccine
GB0228716D0 (en) Vaccine
GB0229594D0 (en) Vaccine
GB0230170D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)